ClinicalTrials.gg
CompletedNCT00912093Updated Jun 11, 2021Results posted

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

A Phase 3 interventional study of Icatibant and Placebo in Hereditary Angioedema, sponsored by Shire. Completed at 64 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.

Enrollment
2nd of 10
98 · median 26
Started
2009
with 1 other
Phase 3
7 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
7 of 10
Shire

Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one is the 2nd largest by enrollment, is one of 2 that started in 2009, is one of 7 in phase 3, and was the 3rd registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →

About icatibant

icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing icatibant in Angioedemas, Hereditary as a file.
02

Study summary

This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE).

Read the detailed description

This Phase III study consisted of two parts: A controlled phase and an open label extension (OLE) phase.

The controlled phase describes the double blind part of the study and was intended to evaluate the efficacy and safety of icatibant compared with placebo for the first treated cutaneous and/or abdominal attack.

Patients with moderate to severe abdominal or cutaneous attacks were randomized to receive a single, blinded, subcutaneous injection of icatibant (30 mg) or placebo. After a protocol amendment, patients with mild to moderate laryngeal HAE attacks were also randomized to receive a single, blinded subcutaneous injection of icatibant (30 mg) or placebo in order to obtain blinded, controlled efficacy and safety data for this subset of subjects. Patients experiencing severe laryngeal attacks (post-amendment) or mild to severe laryngeal attacks (pre-amendment) were to receive open-label icatibant.

After treatment of the first attack in the controlled phase, patients were eligible to enter the OLE phase. In the OLE phase, patients who experienced angioedema attacks severe enough to warrant treatment were to be treated with s.c. icatibant as appropriate until the study was discontinued or the product was commercially available.

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • HAE
  • Type I HAE
  • Type II HAE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each patient must meet the following criteria to be enrolled in this study.

  1. The patient is ≥18 years old at the time of .
  2. The patient has a documented diagnosis of HAE type I or II. The diagnosis will be confirmed either by documented decreased C4 levels and/or immunogenic or functional C1-INH deficiency results (\<50% of normal levels) consistent with HAE types I and II or by medical history.
  3. The current HAE attack must be in the cutaneous, abdominal and/or laryngeal (inclusive of laryngeal and pharyngeal) areas.
  4. Cutaneous or abdominal HAE attacks must be moderate to very severe as determined by investigator global assessment at pre-treatment assessments
  5. The patient must report at least 1 VAS score ≥ 30mm
  6. The patient commences treatment within 6 hours of the attack becoming at least mild (laryngeal) or moderate (non-laryngeal) in severity, but not more than 12 hours after the onset of the attack.
  7. Women of must have a negative urine pregnancy test and must use appropriate methods to prevent pregnancy during their participation in the study.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study.

  1. The patient has a diagnosis of angioedema other than HAE type I or II.
  2. The patient has received previous treatment with icatibant.
  3. The patient has participated in a clinical trial and has received treatment with another medicinal product within the past 30 days.
  4. The patient has received treatment with any pain medication since the onset of the current angioedema attack.
  5. The patient has received replacement therapy (fresh frozen plasma [FFP], C1-INH products) less than 5 days (120 hours) from the onset of the current angioedema attack.
  6. The patient is receiving treatment with angiotensin converting enzyme (ACE) inhibitors.
  7. Evidence of coronary artery disease based on medical history or screening examination in particular unstable angina pectoris or severe coronary heart disease;
  8. The patient has a serious concomitant illness or condition that, in the opinion of the Investigator, would be a for participation in the trial.
  9. The patient is pregnant or breastfeeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Single subcutaneous injection of matching placebo

    Drug: Placebo

  • Experimental
    Icatibant

    Single subcutaneous injection of icatibant, 30 mg

    Drug: Icatibant

Interventions

  • Single subcutaneous injection of icatibant, 30 mg

    Also known as: Firazyr

  • DrugPlacebo

    Single subcutaneous injection of matching placebo

06

What researchers measure

Primary outcomes

  1. Time to Onset of Symptom Relief for an Acute Attack, as Assessed by the Patient

    Time to onset of symptom relief was calculated from study drug administration to onset of symptom relief, where onset of symptom relief was defined as the earliest of 3 consecutive measurements in which there was a 50% reduction from pretreatment in composite VAS score. Composite VAS score comprised 3 symptoms, including skin swelling, skin pain, and abdominal pain, for cutaneous and abdominal attacks and 5 symptoms, including skin swelling, skin pain, abdominal pain, difficulty swallowing, and voice change, for laryngeal attacks. Subjects who did not achieve symptom relief within the observation period were censored at the last observation time.

    Time frame: Up to 120 hours post-dose

Secondary outcomes

  1. Time to Onset of Primary Symptom Relief

    Time to primary symptom relief was calculated from the time of study drug administration to the onset of primary symptom relief, where onset of primary symptom relief was determined using the subject-assessed VAS score for a single primary symptom (determined by edema location) and defined as the earliest of 3 consecutive non-missing measurements in which a pre-specified reduction from the pretreatment value was met. Subjects who did not achieve primary symptom relief within the observation period were censored at the last observation time.

    Time frame: Up to 120 hours post-dose

  2. Time to Almost Complete Symptom Relief

    Time to almost complete symptom relief was calculated from the time of study drug administration to almost complete symptom relief, where almost complete symptom relief was defined as the earliest of 3 consecutive non-missing measurements in which all VAS scores \<10 mm. Subjects who did not achieve almost complete symptom relief within the observation period were censored at the last observation time.

    Time frame: Up to 120 Hours post treatment

  3. Time to Subject-Assessed Initial Symptom Improvement

    Time to initial symptom improvement was calculated from the time of study drug administration to initial symptom improvement as determined by the subject as the time they felt symptoms were starting to improve. Subjects who did not achieve initial symptom improvement within the observation period were censored at the last observation time.

    Time frame: Up to 120 hours post-dose

  4. Time to Investigator-Assessed Initial Symptom Improvement

    Time to initial symptom improvement was calculated from the time of study drug administration to initial symptom improvement as determined by the investigator as the time they felt symptoms were starting to improve. Subjects who did not achieve initial symptom improvement within the observation period were censored at the last observation time.

    Time frame: Up to 120 hours post-dose

07

Results

Posted Aug 6, 2014

Participant flow

The Controlled Phase
Participant flow — The Controlled Phase
MilestoneRandomized-Icatibant (Blinded Treatment)-Non-laryngealRandomized-Placebo (Blinded Treatment)-Non-laryngealRandomized-Icatibant (Blinded Treatment)-LaryngealRandomized-Placebo (Blinded Treatment)-LaryngealOpen-Label Icatibant-Severe Laryngeal
Started4345325
Completed4343324
Not completed02001
Withdrew: Death01000
Withdrew: Medical condition01000
Withdrew: Lost to follow-up00001
The Open Label Extension (OLE) Phase
Participant flow — The Open Label Extension (OLE) Phase
MilestoneRandomized-Icatibant (Blinded Treatment)-Non-laryngealRandomized-Placebo (Blinded Treatment)-Non-laryngealRandomized-Icatibant (Blinded Treatment)-LaryngealRandomized-Placebo (Blinded Treatment)-LaryngealOpen-Label Icatibant-Severe Laryngeal
Started3835324
Completed3835324
Not completed00000

Outcome measures

PrimaryTime to Onset of Symptom Relief for an Acute Attack, as Assessed by the Patient

Time to onset of symptom relief was calculated from study drug administration to onset of symptom relief, where onset of symptom relief was defined as the earliest of 3 consecutive measurements in which there was a 50% reduction from pretreatment in composite VAS score. Composite VAS score comprised 3 symptoms, including skin swelling, skin pain, and abdominal pain, for cutaneous and abdominal attacks and 5 symptoms, including skin swelling, skin pain, abdominal pain, difficulty swallowing, and voice change, for laryngeal attacks. Subjects who did not achieve symptom relief within the observation period were censored at the last observation time.

Time frame:
Up to 120 hours post-dose
Reported as:
Median · Hours
Time to Onset of Symptom Relief for an Acute Attack, as Assessed by the Patient
HoursRandomized-Icatibant (Blinded Treatment)--Non-laryngealRandomized-Placebo (Blinded Treatment)-Non-laryngeal
Time to Onset of Symptom Relief for an Acute Attack, as Assessed by the Patient2.0 (1.5 to 3.0)19.8 (6.1 to 26.3)
Statistical analysis
  • Randomized-Icatibant (Blinded Treatment)--Non-laryngeal vs Randomized-Placebo (Blinded Treatment)-Non-laryngeal · Peto-Peto Wilcoxon · p = <0.001
SecondaryTime to Onset of Primary Symptom Relief

Time to primary symptom relief was calculated from the time of study drug administration to the onset of primary symptom relief, where onset of primary symptom relief was determined using the subject-assessed VAS score for a single primary symptom (determined by edema location) and defined as the earliest of 3 consecutive non-missing measurements in which a pre-specified reduction from the pretreatment value was met. Subjects who did not achieve primary symptom relief within the observation period were censored at the last observation time.

Time frame:
Up to 120 hours post-dose
Reported as:
Median · Hours
Time to Onset of Primary Symptom Relief
HoursRandomized-Icatibant (Blinded Treatment)--Non-laryngealRandomized-Placebo (Blinded Treatment)-Non-laryngeal
Time to Onset of Primary Symptom Relief1.5 (1.0 to 2.0)18.5 (3.6 to 23.9)
Statistical analysis
  • Randomized-Icatibant (Blinded Treatment)--Non-laryngeal vs Randomized-Placebo (Blinded Treatment)-Non-laryngeal · Peto-Peto Wilcoxon · p = <0.001
SecondaryTime to Almost Complete Symptom Relief

Time to almost complete symptom relief was calculated from the time of study drug administration to almost complete symptom relief, where almost complete symptom relief was defined as the earliest of 3 consecutive non-missing measurements in which all VAS scores \<10 mm. Subjects who did not achieve almost complete symptom relief within the observation period were censored at the last observation time.

Time frame:
Up to 120 Hours post treatment
Reported as:
Median · Hours
Time to Almost Complete Symptom Relief
HoursRandomized-Icatibant (Blinded Treatment)--Non-laryngealRandomized-Placebo (Blinded Treatment)-Non-laryngeal
Time to Almost Complete Symptom Relief8.0 (5.0 to 42.5)36.0 (29.0 to 50.9)
Statistical analysis
  • Randomized-Icatibant (Blinded Treatment)--Non-laryngeal vs Randomized-Placebo (Blinded Treatment)-Non-laryngeal · Peto Peto Wilcoxon · p = 0.012
SecondaryTime to Subject-Assessed Initial Symptom Improvement

Time to initial symptom improvement was calculated from the time of study drug administration to initial symptom improvement as determined by the subject as the time they felt symptoms were starting to improve. Subjects who did not achieve initial symptom improvement within the observation period were censored at the last observation time.

Time frame:
Up to 120 hours post-dose
Reported as:
Median · Hours
Time to Subject-Assessed Initial Symptom Improvement
HoursRandomized-Icatibant (Blinded Treatment)--Non-laryngealRandomized-Placebo (Blinded Treatment)-Non-laryngeal
Time to Subject-Assessed Initial Symptom Improvement0.8 (0.5 to 1.0)3.5 (1.9 to 5.4)
Statistical analysis
  • Randomized-Icatibant (Blinded Treatment)--Non-laryngeal vs Randomized-Placebo (Blinded Treatment)-Non-laryngeal · Peto-Peto Wilcoxon · p = <0.001
SecondaryTime to Investigator-Assessed Initial Symptom Improvement

Time to initial symptom improvement was calculated from the time of study drug administration to initial symptom improvement as determined by the investigator as the time they felt symptoms were starting to improve. Subjects who did not achieve initial symptom improvement within the observation period were censored at the last observation time.

Time frame:
Up to 120 hours post-dose
Reported as:
Median · Hours
Time to Investigator-Assessed Initial Symptom Improvement
HoursRandomized-Icatibant (Blinded Treatment)--Non-laryngealRandomized-Placebo (Blinded Treatment)-Non-laryngeal
Time to Investigator-Assessed Initial Symptom Improvement0.8 (0.6 to 1.3)3.4 (2.6 to 6.0)
Statistical analysis
  • Randomized-Icatibant (Blinded Treatment)--Non-laryngeal vs Randomized-Placebo (Blinded Treatment)-Non-laryngeal · Peto-Peto Wilcoxon · p = <0.001

Adverse events

Collected over Treatment emergent adverse events occurring within 16 days of study drug administration are included in the analysis. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Controlled Phase - Icatibant (Randomized)—0/46 (0%)8/46 (17.4%)
Controlled Phase -Placebo (Randomized)—5/46 (10.9%)12/46 (26.1%)
Controlled Phase - Icatibant (Open Label)—0/6 (0%)0/6 (0%)
Open Label Extension - Icatibant (Open Label)—7/82 (8.5%)23/82 (28%)
Most frequent serious events
Most frequent serious events
EventControlled Phase - Icatibant (Randomized)Controlled Phase -Placebo (Randomized)Controlled Phase - Icatibant (Open Label)Open Label Extension - Icatibant (Open Label)
Hereditary angioedemaCongenital, familial and genetic disorders0/462/460/63/82
Myocardial infarctionCardiac disorders0/461/460/60/82
GastroenteritisInfections and infestations0/461/460/60/82
TracheostomySurgical and medical procedures0/461/460/60/82
ArrhythmiaCardiac disorders0/460/460/61/82
Non-Cardiac Chest PainGeneral disorders0/460/460/61/82
PneumoniaRespiratory, thoracic and mediastinal disorders0/460/460/61/82
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/460/460/61/82
CholecystitisHepatobiliary disorders0/460/460/61/82
Most frequent other events
Most frequent other events
EventControlled Phase - Icatibant (Randomized)Controlled Phase -Placebo (Randomized)Controlled Phase - Icatibant (Open Label)Open Label Extension - Icatibant (Open Label)
Hereditary angioedemaCongenital, familial and genetic disorders5/469/460/611/82
HeadacheNervous system disorders3/463/460/69/82
Upper Respiratory Tract InfectionInfections and infestations0/460/460/65/82

Baseline characteristics

Age, Continuous
Age, Continuous(years)Randomized-Icatibant (Blinded Treatment)--Non-laryngealRandomized-Placebo (Blinded Treatment)-Non-laryngealRandomized-Icatibant (Blinded Treatment)--LaryngealRandomized-Placebo (Blinded Treatment)-LaryngealOpen-Label Icatibant-Severe LaryngealTotal
Mean36.1 ± 13.6936.6 ± 11.1840.3 ± 6.6650.0 ± 22.6341.6 ± 11.7837.0 ± 12.46
Sex: Female, Male
Sex: Female, Male(Participants)Randomized-Icatibant (Blinded Treatment)--Non-laryngealRandomized-Placebo (Blinded Treatment)-Non-laryngealRandomized-Icatibant (Blinded Treatment)--LaryngealRandomized-Placebo (Blinded Treatment)-LaryngealOpen-Label Icatibant-Severe LaryngealTotal
Female272921261
Male161611337
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Randomized-Icatibant (Blinded Treatment)--Non-laryngealRandomized-Placebo (Blinded Treatment)-Non-laryngealRandomized-Icatibant (Blinded Treatment)--LaryngealRandomized-Placebo (Blinded Treatment)-LaryngealOpen-Label Icatibant-Severe LaryngealTotal
American Indian or Alaska Native000000
Asian000000
Black or African American300003
Native Hawaiian or Other Pacific000000
White384032487
Other250018
Region of Enrollment
Region of Enrollment(Participants)Randomized-Icatibant (Blinded Treatment)--Non-laryngealRandomized-Placebo (Blinded Treatment)-Non-laryngealRandomized-Icatibant (Blinded Treatment)--LaryngealRandomized-Placebo (Blinded Treatment)-LaryngealOpen-Label Icatibant-Severe LaryngealTotal
United States263222365
Hungary310004
Canada100001
Ukraine010001
Romania311005
Australia230005
Russian Federation210003
South Africa210014
Israel4500110
Weight (kg)
Weight (kg)(Participants)Randomized-Icatibant (Blinded Treatment)--Non-laryngealRandomized-Placebo (Blinded Treatment)-Non-laryngealRandomized-Icatibant (Blinded Treatment)--LaryngealRandomized-Placebo (Blinded Treatment)-LaryngealOpen-Label Icatibant-Severe LaryngealTotal
<= 50 kg420006
>50-75 kg162012039
>75-100 kg141310331
>100 kg91010222
08

Study locations

64 sites
  • Primary Care Associates of Alabaster
    Alabaster, Alabama 35007, United States
  • UAB Lung Health Center
    Birmingham, Alabama 35294, United States
  • Medical Research of AZ A Division of Allergy & Immunology Assoc
    Scottsdale, Arizona 85251, United States
  • Little Rock Allergy & Asthma Clinic, PA
    Little Rock, Arkansas 72205, United States
  • Allergy and Asthma Insititute of the Valley
    Granada Hills, California 91344, United States
  • University of California San Diego
    La Jolla, California 92093, United States
  • UCLA - Clinical Immunology & Allergy
    Los Angeles, California 90095, United States
  • Speciality Medical Clinic & Research Center
    Stanford, California 27330, United States
  • Standford University
    Stanford, California 94305, United States
  • Asthma & Allergy Associates, PC
    Colorado Springs, Colorado 80907, United States
  • Medical Associates of Brevard
    Melbourne, Florida 32935, United States
  • University of South Florida Division of Allergy and Immunology
    Tampa, Florida 33613, United States
  • Family Allergy and Asthma Center, PC
    Atlanta, Georgia 30342, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Research Institute of Deaconess Clinic
    Evansville, Indiana 47713, United States
  • University of Iowa Asthma Center/ Hospitals & Clinics
    Iowa City, Iowa 52242, United States
  • LSUHSC Allergy & Immunology
    Shreveport, Louisiana 71130, United States
  • Institute for Asthman & Allergy, P.C.
    Chevy Chase, Maryland 20815-6901, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • The Asthma Center
    Saint Louis, Missouri 63141, United States
  • University of Reno Nevada School of Medicine
    Reno, Nevada 89503, United States
  • STARx Research Center, LLC
    Edison, New Jersey 08820, United States
  • Montefiore Medical Center/Albert Einstein College of Medicine
    Bronx, New York 10461, United States
  • Winthrop University Hospital Clinical Trials Center
    Mineola, New York 11501, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Allergy Partners of Western North Carolina
    Asheville, North Carolina 28801, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Cincinnati Division of Immunology/Allergy
    Cincinnati, Ohio 45267, United States
  • Optimed Research, LTD
    Columbus, Ohio 43235, United States
  • Tulsa Allergy Clinic
    Tulsa, Oklahoma 74133, United States
  • Baker Allergy, Asthma & Dermatology Research Center LLC
    Lake Oswego, Oregon 97035, United States
  • Valley Clinical Research Center
    Bethlehem, Pennsylvania 18020, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Children's Hospital of Pittsburgh (of UMPC)
    Pittsburgh, Pennsylvania 15224, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • University of Texas Medical Branch (UTMB)
    Galveston, Texas 77555-0561, United States
  • Texas A&M Health Science Center College of Medicine
    Houston, Texas 77030, United States
  • Allergy and Asthma Research Center, P.A.
    San Antonio, Texas 78229, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Canberra Hospital Department of Immunology
    Garran, Australian Capital Territory, Australia
  • Dept of Medicine Immunology & Allergy Campbelltown Hospital
    Campbelltown, New South Wales 2560, Australia
  • Royal Melbourne Hospital Department of Immunology
    Parkville, Victoria 3050, Australia
  • Royal Adelaide Hospital
    Adelaide, Australia
  • NACTRC
    Edmonton, Alberta T6G 2H7, Canada
  • Allergy & Asthma Research Centre
    Ottawa, Ontario K1Y 4G2, Canada
  • Centre de recherché Appliquée en allergie de Québec
    Quebec City, Quebec G1V 5M6, Canada
  • 3rd Department of Internal Medicine Semmelweis University
    Budapest, 1125, Hungary
  • Bnai-Zion Medical Center Division of Immunology & Allergy
    Haifa, 31048, Israel
  • Tel Aviv Medical Center
    Tel Aviv, 64239, Israel
  • The Chaim Sheba Medical Center
    Tel Hashomer, 52621, Israel
  • Spitalul Clinic Judetean Mures Sectia Medicina Interna
    Targu Mures, Transylvania 540103, Romania
  • Medical Academy of Postgraduate Education
    St Petersburg, Saint Petersburg 194291, Russian Federation
  • Autonomous Non Commercial Organization
    St Petersburg, Saint Petersburg 198216, Russian Federation
  • State Healthcare Institution of City of Moscow
    Moscow, 115446, Russian Federation
  • State Enterprise State Scientific Centre
    Moscow, 115478, Russian Federation
  • State Educational Institution of Additional Profess. Edu. Moscow
    Moscow, 123182, Russian Federation
  • Municipal Medical & Preventive Treatment Institution
    Smolensk, 214001, Russian Federation
  • Regional Clinical Center of Specialized Medical Treatment
    Vladivostok, 690091, Russian Federation
  • Allergy Diagnostic and Clinical Research Unit (ADCRU)
    Cape Town, Mowbray 7700, South Africa
  • Ivano-Frankivsk national Medical University
    Ivano-Frankivsk, 76018, Ukraine
  • National Medical Academy for Postgraduate Education
    Kyiv, 01133, Ukraine
  • Institute of Otolaryngology
    Kyiv, 03680, Ukraine
  • Ukranian Medical Stomatological Academy Dept of Int Diseases
    Poltava, 36039, Ukraine
  • Vinnitsa Medical Academy Chair of Internal Disease
    Vinnitsa, 21029, Ukraine
09

References and documents

Publications

  • Lumry WR, Farkas H, Moldovan D, Toubi E, Baptista J, Craig T, Riedl M. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3. Int Arch Allergy Immunol. 2015;168(1):44-55. doi: 10.1159/000441060. Epub 2015 Nov 11. PubMed 26556097 ↗
  • Maurer M, Longhurst HJ, Fabien V, Li HH, Lumry WR. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting. Allergy Asthma Proc. 2014 Sep-Oct;35(5):377-81. doi: 10.2500/aap.2014.35.3780. Epub 2014 Aug 6. PubMed 25198193 ↗
  • Bas M. Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial. Expert Rev Clin Immunol. 2012 Nov;8(8):707-17. doi: 10.1586/eci.12.67. PubMed 23167682 ↗
  • Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, Riedl M, Li H, Craig T, Bloom BJ, Reshef A. Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011 Dec;107(6):529-37. doi: 10.1016/j.anai.2011.08.015. Epub 2011 Oct 5. PubMed 22123383 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2009 to primary completion in Oct 2010, 14 months.

Results were first posted in Aug 2014, 3 years 10 months after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 14 months is below that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2009
First posted
Jun 3, 2009
StartActual
Jul 16, 2009
Primary completionActual
Oct 1, 2010
CompletionActual
Oct 1, 2010
Results first posted
Aug 6, 2014
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00912093
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jun 3, 2009
Start date
Jul 16, 2009
Primary completion
Oct 1, 2010
Completion
Oct 1, 2010
Results posted
Aug 6, 2014
Last update
Jun 11, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icatibant

Start the discussion